Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 2 » Issue 3

Religiosity in patients with Parkinson's disease

Authors Patrick McNamara, Raymon Durso, Ariel Brown

Published Date October 2006 Volume 2006:2(3) Pages 341—348

DOI

Published 10 October 2006

Patrick McNamara, Raymon Durso, Ariel Brown

Department of Neurology, Boston University School of Medicine, Boston, MA, and VA Boston Healthcare System, Boston, MA, USA

Objective: To study clinical correlates of religiosity in Parkinson’s disease (PD).

Methods: Measures of life goals, religiosity, mood, and neuropsychologic function were assessed in 22 persons with mid-stage PD and 20 age-matched healthy controls. Levodopa dose equivalents (LDE) were also computed for the patients.

Results: Relative to other major life goals parkinsonian patients were significantly more likely to report that “my religion or life philosophy” was less important than were age-matched controls. Scores on a battery of religiosity scales were consistently lower for Parkinson’s patients than those of age-matched controls. While Mini Mental State Exam, logical memory recall, Stroop, and selected (depression and anxiety) mood scales reliably distinguished patients from controls, only measures of prefrontal function correlated with religiosity scores.

Conclusions: Patients with PD express less interest in religion and report consistently lower scores on measures of religiosity than age-matched controls. Prefrontal dopaminergic networks may support motivational aspects of religiosity.

Keywords: religiosity, Parkinson’s disease, neuropsychology, mood, executive functions, dopamine agonists

Download Article [PDF] 

Readers of this article also read:

Withdrawal of sulfonylureas from patients with type 2 diabetes receiving long-term sulfonylurea and insulin combination therapy results in deterioration of glycemic control: a randomized controlled trial

Srivanichakorn W, Sriwijitkamol A, Kongchoo A, Sriussadaporn S, Plengvidhya N, Lertwattanarak R, Vannasaeng S, Thongtang N

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2015, 8:137-145

Published Date: 2 March 2015

Tat peptide-decorated gelatin-siloxane nanoparticles for delivery of CGRP transgene in treatment of cerebral vasospasm [Corrigendum]

Tian XH, Wang ZG, Meng H, Wang YH, Feng W, Wei F, Huang ZC, Lin XN, Ren L

International Journal of Nanomedicine 2013, 8:2129-2130

Published Date: 13 June 2013

Corrigendum

Wu Q, Chu M

International Journal of Nanomedicine 2012, 7:4531-4532

Published Date: 15 August 2012

Erratum

Marusza W, Mlynarczyk G, Olszanski R, Netsvyetayeva I, Obrowski M, Iannitti T, Palmieri B

International Journal of Nanomedicine 2012, 7:4119-4120

Published Date: 27 July 2012

The effect of intravitreal anti-VEGF agents on peripheral wound healing in a rabbit model

Christoforidis J, Ricketts R, Pratt C, Pierce J, Bean S, Wells M, Zhang X, La Perle K

Clinical Ophthalmology 2012, 6:61-69

Published Date: 10 January 2012

Erratum

RA Kurt, K Gündüz

Clinical Ophthalmology 2010, 4:981-982

Published Date: 6 September 2010

Corrigendum

Dove Medical Press Editorial

Clinical Interventions in Aging 2008, 3:397-397

Published Date: 30 June 2008